Totapally Balagangadhar R, Nadiger Meghana, Hassor Sophia, Laufer Marcelo, Etinger Veronica, Ramos Otto, Biehler Jefry, Meyer Keith, Melnick Steven
Division of Critical Care Medicine, Nicklaus Children's Hospital, Miami, Florida, United States.
Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, United States.
J Pediatr Intensive Care. 2021 Jun 19;12(2):137-147. doi: 10.1055/s-0041-1730932. eCollection 2023 Jun.
The aim of this study is to describe characteristics and hospital course of children admitted with COVID-19 to a tertiary care pediatric center in Southeastern United States, and to present the frequency of three classes of multisystem inflammatory syndrome in children (MIS-C) and develop pediatric COVID-19 associated hyperinflammation score (PcHIS). A retrospective cohort study of 68 children was performed. Critical illness was defined as any child requiring respiratory or cardiovascular support or renal replacement therapy. PcHIS was developed by using six variables: fever, hematological dysfunction, coagulopathy, hepatic injury, macrophage activation, and cytokinemia. Centers for Disease Control and Prevention criteria were used to identify MIS-C, and three classes of MIS-C were identified based on the findings of recently published latent class analysis (Class 1: MIS-C without Kawasaki like disease, Class 2: MIS-C with respiratory disease, and Class 3: MIS-C with Kawasaki like disease). The median age was 6.4 years. Fever, respiratory, and gastrointestinal were common presenting symptoms. MIS-C was present in 32 (47%), critical COVID-19 illness in 11 (16%), and 17 (25%) were admitted to the PICU. Children with critical illness were adolescents with elevated body mass index and premorbid conditions. PcHIS score of 3 had a sensitivity of 100% and a specificity of 77% for predicting critical COVID-19 illness. Among MIS-C patients, 15 (47%) were in Class 1, 8 (25%) were in Class 2, and 9 (28%) were in Class 3. We conclude that most children with COVID-19 have mild-to-moderate illness. Critical COVID-19 is mainly seen in obese adolescents with premorbid conditions. Three Classes of MIS-C are identifiable based on clinical features. Validation and clinical implication of inflammation score in pediatric COVID-19 need further investigation.
本研究旨在描述美国东南部一家三级医疗儿科中心收治的新冠病毒病(COVID-19)患儿的特征及住院病程,呈现儿童多系统炎症综合征(MIS-C)三类病症的发生率,并制定儿童COVID-19相关高炎症评分(PcHIS)。对68名儿童进行了一项回顾性队列研究。危重症定义为任何需要呼吸或心血管支持或肾脏替代治疗的儿童。PcHIS通过使用六个变量制定:发热、血液学功能障碍、凝血病、肝损伤、巨噬细胞活化和细胞因子血症。采用疾病控制与预防中心的标准来识别MIS-C,并根据最近发表的潜在类别分析结果确定了三类MIS-C(第1类:无川崎病样疾病的MIS-C,第2类:伴有呼吸系统疾病的MIS-C,第3类:伴有川崎病样疾病的MIS-C)。中位年龄为6.4岁。发热、呼吸道和胃肠道症状是常见的首发症状。32名(47%)患儿患有MIS-C,11名(16%)患有危重症COVID-19,17名(25%)入住儿科重症监护病房(PICU)。危重症患儿为青少年,体重指数升高且有基础疾病。PcHIS评分为3时,预测危重症COVID-19疾病的敏感性为100%,特异性为77%。在MIS-C患者中,15名(47%)属于第1类,8名(25%)属于第2类,9名(28%)属于第3类。我们得出结论,大多数COVID-19患儿病情为轻至中度。危重症COVID-19主要见于有基础疾病的肥胖青少年。基于临床特征可识别出三类MIS-C。儿科COVID-19炎症评分的验证及其临床意义需要进一步研究。